The law normally requires people who offer financial products to give information to investors before they invest. This requires those offering financial products to have disclosed information that is important for investors to make an informed decision. The usual rules do not apply to this offer if you are a person who comes within Schedule1, clause 3(2)(a)-(c) or 3(3)(a)-(b)(ii) (inclusive) of the Financial Markets Conduct Act 2013. This includes where the amount invested upfront by the investor (plus any other investments the Investor has already made in the financial products) is $750,000 or more. If you fall within Schedule 1, clause 3 of the FMCA as a result of this exclusion, you may not receive a complete and balanced set of information. You will also have fewer other legal protections for this investment. Investments of this kind are not suitable for retail investors. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.
InsituGen is redefining steroid hormone diagnostics through a multi-patented, breakthrough bioassay platform that detects hormone activity where current technologies fail. Existing endocrine tests are slow, insensitive, expensive, and unable to measure functional bioactivity or detect unknown hormonal mimics. InsituGen eliminates these limitations, opening an addressable market valued at more than US$21B across animal health, human health, environmental monitoring, and consumer product safety.
The company’s first commercial product—NeuterReady™—has launched in New Zealand and the UK, providing veterinarians and pet owners with rapid, accurate detection of hormonal maturity. This directly addresses a >US$2B unmet medical need in companion animal hormone health. More than 100 million dogs globally are neutered or spayed without hormonal assessment, and current tests are unable to guide optimal timing. InsituGen solves this gap and is advancing a full suite of life-stage diagnostics including SpayReady, SpayCheck, and LongevityAnnual.
InsituGen has delivered milestones across successive investment rounds and is now raising NZ$2M to scale commercial rollout, expand globally into AUS, Germany and the US, and accelerate point-of-care development. With strong recurring revenue potential, multi-vertical applications, no direct competition, and a globally scalable platform, InsituGen offers investors the opportunity to participate early in a technology poised to transform hormone-based diagnostics.
To learn more about this opportunity and speak with one of the Pacific Channel team, register your interest below.
You are almost registered. Please complete the following details.
An online platform for the private marketplace, enabling investing, divesting and capital raising in proportionally owned structures.
Sign up for our weekly newsletter and let your in next investment come directly to your inbox.
